Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.
about
Experience with biosimilar infliximab (CT-P13) in paediatric patients with inflammatory bowel diseasesComparative effectiveness research with administrative health data in rheumatoid arthritis.Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.Is there a reason for concern or is it just hype? - A systematic literature review of the clinical consequences of switching from originator biologics to biosimilars.The safety of tumor necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis.Sarcoidosis: an update on current pharmacotherapy options and future directions.A Critical Review of Biosimilars in IBD: The Confluence of Biologic Drug Development, Regulatory Requirements, Clinical Outcomes, and Big Business.Infliximab Biosimilar (CT-P13; Infliximab-dyyb): A Review in Autoimmune Inflammatory Diseases.The totality-of-the-evidence approach to the development and assessment of GP2015, a proposed etanercept biosimilar.Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.Systematic review with meta-analysis: the efficacy and safety of CT-P13, a biosimilar of anti-tumour necrosis factor-α agent (infliximab), in inflammatory bowel diseases.Rheumatologists' Perceptions of Biosimilar Medicines Prescription: Findings from a French Web-Based Survey.Reviewing the evidence for biosimilars: key insights, lessons learned and future horizons.A review on biosimilar infliximab, CT-P13, in the treatment of inflammatory bowel disease.The process defines the product: what really matters in biosimilar design and production?Drug concentrations and anti-drug antibodies during treatment with biosimilar infliximab (CT-P13) in routine care.A biosimilarity index for psoriasis.Knowledge, behaviors and practices of community and hospital pharmacists towards biosimilar medicines: Results of a French web-based survey.Cost-effectiveness of biological treatment sequences for fistulising Crohn's disease across Europe.Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis.
P2860
Q28066776-104B0E6A-178F-4F09-9A71-CC9B8C1189B0Q31077662-85F79E13-7428-4A3D-9296-D5CCEC78034FQ38647397-985E2262-6E18-4540-9C61-CD11B3719D1DQ38708927-792407AF-25E8-480B-84DB-88DC0CB70827Q38755133-C9E1C760-056C-497E-A284-3FF4DC07D68CQ38798146-E1922196-E043-45A8-9309-17EBB88DB9DEQ38937842-E0EEEC8A-60C7-45A7-8807-96F8B090BE9CQ38960108-A64DA191-D0B5-446D-83A5-C1FFCE18E56AQ38992643-DFF24BB3-B375-403A-8F50-9BF5DA8FE1FDQ39016810-3AA85427-452D-411D-A8BA-8FACC1E481F9Q39152159-DD864237-6A7F-46ED-8779-9D5110066E1BQ39184810-3186BF70-FF86-46C4-9FAC-11704237CD25Q47807650-7D64D189-A996-4812-B05C-C101A55E08B0Q50073683-E2B997B7-5233-49FA-BB1A-8E84AD1A79CBQ50115805-2FC8C700-5A04-49F4-A502-11B52C4E4CDAQ50135901-07989B6A-7B3C-4360-BC5D-AC8409BA80C2Q50204734-BE5EFDA9-CA0A-4544-B5D0-D4C9A9BD9759Q51022840-75C9C469-434B-4398-8D0A-5675AF78C6CEQ52670879-31807646-679C-4757-B1C9-F3B0C59157C0Q52900365-452FD314-64CF-43B3-B9FB-38E9812C7AB6
P2860
Biosimilars in immune-mediated inflammatory diseases: initial lessons from the first approved biosimilar anti-tumour necrosis factor monoclonal antibody.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Biosimilars in immune-mediated ...... is factor monoclonal antibody.
@en
type
label
Biosimilars in immune-mediated ...... is factor monoclonal antibody.
@en
prefLabel
Biosimilars in immune-mediated ...... is factor monoclonal antibody.
@en
P2093
P2860
P356
P1476
Biosimilars in immune-mediated ...... sis factor monoclonal antibody
@en
P2093
P2860
P356
10.1111/JOIM.12432
P407
P577
2015-09-25T00:00:00Z